MedCity News March 12, 2025
Roche will share in developing and commercializing petrelintide, a clinical-stage Zealand Pharma drug that activates the amylin receptor to spark weight loss. This agreement represents the highest total financial consideration in the obesity field to date.
Roche is expanding its scope to a promising but competitive new obesity target, committing $1.65 billion up front to partner on a clinical-stage Zealand Pharma molecule with the potential to be a standalone treatment and part of drug combinations for weight loss.
The deal announced Wednesday calls for the companies to share in the development and commercialization of the Zealand drug, petrelintide. The partners will co-commercialize the drug in the U.S. and Europe; Roche is gaining commercialization rights in the rest of the world....
Today's Sponsors
Today's Sponsor